ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

Core Insights - ViaNautis Bio has entered a strategic collaboration with Eli Lilly to utilize its polyNaut® platform for developing targeted genetic medicines [1][2] - The collaboration includes an initial upfront payment and potential future milestone payments based on research achievements and commercialization of products [2] - The polyNaut® technology aims to enhance the delivery of genetic materials, potentially transforming treatment options for various diseases [3][6] Company Overview - ViaNautis Bio, founded in 2018 as a spin-off from UCL, focuses on leveraging its polyNaut® technology for targeted genetic medicine delivery [5] - The polyNaut® platform is designed for precise intracellular delivery, capable of encapsulating a wide range of genetic cargoes and small molecules [6] - The technology distinguishes itself by effectively targeting specific cells and overcoming biological barriers, including the blood-brain barrier [7] Collaboration Details - The collaboration with Lilly is expected to accelerate the development of novel therapies for severe life-limiting diseases by combining ViaNautis' scientific expertise with Lilly's drug development capabilities [4] - ViaNautis is actively building an internal pipeline while collaborating with other pharmaceutical and biotech companies to explore new therapeutic platforms [8]